Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Edgewise Therapeutics's Sevasemten?
Sevasemten is a small molecule commercialized by Edgewise Therapeutics, with a leading Phase III program in Becker Muscular Dystrophy. According...
Sevasemten by Edgewise Therapeutics for Duchenne Muscular Dystrophy: Likelihood of Approval
Sevasemten is under clinical development by Edgewise Therapeutics and currently in Phase II for Duchenne Muscular Dystrophy. According to GlobalData,...
Sevasemten by Edgewise Therapeutics for Becker Muscular Dystrophy: Likelihood of Approval
Sevasemten is under clinical development by Edgewise Therapeutics and currently in Phase III for Becker Muscular Dystrophy. According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Edgewise Therapeutics's Sevasemten?
Sevasemten is a small molecule commercialized by Edgewise Therapeutics, with a leading Phase III program in Becker Muscular Dystrophy. According...